Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tumour-pulsed dendritic cells
- Development stage
- Unknown
- Lead developer
- Affiliated Hospital of Inner Mongolia Medical University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Tumour-pulsed dendritic cells are an experimental autologous cell-based immunotherapy investigated for the treatment of various malignancies, including lymphoma and pancreatic carcinoma. The therapy involves harvesting a patient's own dendritic cells (DCs)—the most potent antigen-presenting cells of the immune system—and "pulsing" them ex vivo with tumor-derived antigens (either from autologous tumor lysate or specific tumor-associated antigens). These pulsed DCs are then matured and re-infused into the patient to prime and activate T-cells, specifically cytotoxic T-lymphocytes (CTLs), to recognize and eliminate tumor cells. In clinical research conducted by institutions like The First Teaching Hospital of Inner Mongolia Medical College, this modality is frequently evaluated in combination with cytokine-induced killer (CIK) cells to enhance the overall anti-tumor immune response.
- Other names
- tumor-pulsed dendritic cellsantigen-pulsed dendritic cellsautologous tumour-pulsed dendritic cells
02
Targets
γδ TCR (T-cell receptor)CD28 (Cluster of Differentiation 28)LFA-1 (Integrin αLβ2)CD40-CD40L (Tumor necrosis factor receptor superfamily member 5 (CD40) and CD40 ligand (CD154))
Beyond the preview
Go deeper on tumour-pulsed dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tumour-pulsed dendritic cells.